Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 14/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25923592 | 1.00 | PRMT5 (0.47) | PRMT5WDR77SLC9A1RIPK1KCNH2 | |
| SCHEMBL30551659 | 1.00 | PRMT5 (0.47) | PRMT5WDR77SLC9A1RIPK1KCNH2 | |
| SCHEMBL25322612 | 0.87 | PRMT5 (0.43) | PRMT5WDR77KCNH2 | |
| SCHEMBL25325890 | 0.86 | PRMT5 (0.38) | PRMT5WDR77RIPK1FFAR2 | |
| SCHEMBL30470544 | 0.85 | PRMT5 (0.45) | PRMT5WDR77RIPK1FFAR2ALDH1A1 | |
| SCHEMBL29081726 | 0.85 | PRMT5 (0.45) | PRMT5WDR77RIPK1FFAR2ALDH1A1 | |
| SCHEMBL24367640 | 0.85 | PRMT5 (0.45) | PRMT5WDR77RIPK1FFAR2ALDH1A1 | |
| SCHEMBL25322454 | 0.85 | RIPK1 (0.50) | PRMT5WDR77RIPK1KCNH2 | |
| SCHEMBL25322450 | 0.85 | RIPK1 (0.50) | PRMT5WDR77RIPK1KCNH2 | |
| SCHEMBL25917618 | 0.85 | RIPK1 (0.50) | PRMT5WDR77RIPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | PRMT5 562/4885WDR77 1925/4885SLC9A1 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.